Contents
He has more than 20 years of experience within academia and industry notably leading clinical development of multiple established vaccines with indications spanning from neonates to older adults and special populations. Dr. Bhuyan most recently oversaw AstraZeneca’s COVID-19, RSV, Influenza and other programs which led to EUA and licensures covering 170+ countries for Vaxzevria , EUAs for Evusheld , and positive pivotal results in three trials supporting a best-in-class RSV mAb. He previously held key leadership roles in vaccines and clinical development at Pfizer, Inovio Pharmaceuticals and Merck where he has led the advancement of programs to Phase 3 and licensure. He notably led the US licensure studies of Trumenba and authored the Phase 3 development of Vaxelis . Dr. Bhuyan is an Adjunct Assistant Professor of Medicine and Infectious Diseases at the University of Pennsylvania where he completed a fellowship in Infectious Diseases.
.jpeg)
Aerium Therapeutics is dedicated to epidemic and pandemic preparedness through the discovery and development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. The Aerium Therapeutics team brings world-class scientists and biotechnology veterans together with experienced investors, with operations in Boston, MA and Lausanne, Switzerland. Aerium’s lead assets are monoclonal antibodies that show broad activity against important variants of concern of SARS-CoV-2 including Omicron and its subvariants BA.1, B.1.1 and BA.2.
Privacy Policy
Dr. Knight was previously at Bristol Myers Squibb where she held roles in Global, U.S. and Europe. She led the global and US approvals of YERVOY , the first immuno-oncology agent. Prior to Bristol Myers Squibb, Dr. Knight’s US regulatory work at Hoffmann-La Roche, Inc., included antiviral and oncology drugs.
F-Prime portfolio companies have seen more than 28 products and drugs approved by regulatory agencies worldwide. Our team of investors, engineers, doctors and scientists is committed to bringing the insight, domain expertise and relationships required to help our companies make a transformational impact. The company emerged from stealth mode with substantial Series A financing backed by founding investor Omega Funds with the participation of F-Prime Capital. Aerium was seeded and incubated by Omega Funds in 2021 and started in collaboration with its two scientific founders, Dr. Giuseppe Pantaleo and Dr. Didier Trono in Switzerland.
Capabilities include a BSL-3/P3 laboratory for advanced viral assays, Cryo-EM expertise for rapid viral protein characterization, and an antibody discovery platform that has already generated Aerium’s promising lead monoclonal antibodies. Aerium is dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats. Our Aerium® PRO essential oil therapeutic diffuser is your ultimate partner in aromatherapy. Benefit from optimal therapeutic efficacy thanks to its cold air, waterless diffusion. Its state-of-the-art technology preserves the natural properties of the essential oils without heating or altering them.
Dr. Honig held several senior level positions in FDA’s Center for Drug Evaluation and Research and was the first Director of the Office of Drug Safety. He is a past President of American Society of Clinical Pharmacology and Therapeutics and is former PhRMA representative to the International Conference on Harmonization Management Committee. Dr. Bhuyan is joining Aerium as the Chief Medical Officer and a member of the executive team. He previously served as Vice President, Head of Clinical Development for Infectious Disease at AstraZeneca.
The aerium 3.0 removes carbon dioxide and produces oxygen as effectively as 25 house plants for a fraction of the cost, time, and space. This product works synergistically with your home garden as the algae can be used as an all-natural organic fertilizer for your plants. F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies. Aerium Therapeutics’ initial efforts are focused on two monoclonal antibodies that, in preclinical testing, have shown potent neutralization of important COVID-19 Variants of Concern , including Delta, Omicron and Omicron’s subvariants BA.1, BA.1.1 and BA.2.
- In preclinical studies, the antibodies have been potent neutralizers of SARS-CoV-2 and its variants.
- Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
- Our Aerium® PRO essential oil therapeutic diffuser is your ultimate partner in aromatherapy.
- October 12, 2021A highly potent antibody effective against SARS-CoV-2 variants of concern.
That group includes Omicron and its sub-variants, among them the BA.2 strain that has been detected in at least 40 countries. Venture-capital firm Omega Funds has created and provided initial funding to Aerium Therapeutics, a biotech startup seeking to develop a broadly effective drug for Covid-19. In pre-clinical studies, the antibodies have been potent neutralisers of SARS-CoV-2 and its variants.
Dr. Albizem was previously Executive Director, Therapeutic Area Operations Leader at Regeneron Pharmaceuticals where he led global study management and clinical operations teams in various therapeutic areas. He was in charge of global clinical operations for the company’s COVID program which received an EUA within one year of initiation. Prior to Regeneron, Dr. Albizem held clinical operations leadership roles at Amgen and lncyte. Dr. Venkayya is the former President of the Global Vaccine Business Unit at Takeda Pharmaceuticals, where he built and led a vertically integrated global business developing vaccines for dengue, norovirus, Zika and pandemic threats.
CUBE Aerium C:68 SLT – First Look
Dr. Venkayya serves as an independent member of the board of CEPI and the International AIDS Vaccine Initiative. He was previously Special Assistant to the President for Biodefense at the White House, where he was the principal author of the National Strategy for Pandemic Influenza. He previously served as Director of Vaccine Delivery at the Bill & Melinda Gates Foundation’s Global Health Program and on the board of Gavi, the Vaccine Alliance. With a pair of prophylactic mAbs for COVID-19 with activity across variants, backing from Omega Funds and pandemic response policy leader Rajeev Venkayya at the helm, new biotech Aerium is taking on the big challenges of COVID-19 therapeutic development and pandemic preparedness.
She has over twenty years of experience in vaccine development and virology, including R&D management, product development and project management. She has worked in biologics development since 2004, with a focus on international product development, technology evaluation, and regulatory, preclinical, and clinical development strategy. Are you looking for an opportunity to make a difference in the global fight against SARS-CoV-2 and future pandemic threats?
.jpeg)
These findings were posted today on BioRXiv and will be submitted to a peer-reviewed journal. Our lead assets are monoclonal antibodies against SARS-CoV-2 with potent neutralizing activity in the laboratory against all variants of concern identified to date, including Delta and Omicron. Called aeriums rather than terrariums because they house Tillandsia “air plants,” they are lightweight and compact, easily hung from a wall with a single nail. The top of the glass is open so that your air plant can be taken out for easy watering, allowing you to create your own perfect wall-mounted display. We continue our “Emerging Industry Leaders” month sponsored by the Sonoran Desert Institute with Carahsoft Partner, Aerium Analytics, a multi-disciplined drone solutions company based in Calgary, Alberta conducting operations across Canada and the U.S. AERIUM specializes in geospatial intelligence, data analytics, visualization and software development to clients in myriad industries.
AERIUM on Dawn of Drones This Week! Integrating Drones and Traditional Aviation for the Airports of the Future
Both scientists are applying their substantial expertise and research capabilities to discover new mAbs against SARS-CoV-2. Dr. Dean is the former Vice President of Discovery Research at Takeda Pharmaceuticals. She was previously Director of New Alliances at the International AIDS Vaccine Initiative, where she directed technology identification efforts across various international collaborative HIV vaccine projects.
A BioNTech executive on Monday confirmed that the company is in discussions with Chinese authorities over regulatory approval of the German biotech firm’s COVID-19 vaccine for use by expatriates in China but the outcome was uncertain. The company plans to develop its two monoclonal antibodies for use in combination to prevent coronavirus infection in people who are immunocompromised and do not make a strong antibody response to vaccines. He left Tokyo-based Takeda Pharmaceutical Co (4502.T) last month after serving as president of its global vaccine business. It’s very easy to set up and the subscription refill makes it easy to maintain.
To be clear, having separately done some work in air quality measurement, my expectations were not that this single device would make a difference in room level CO2. Perhaps it consumes CO2 equivalent to having 25 plants- that’s good but one would need to get to high hundreds to low thousands of plant-equivalents to make a human-noticeable dent in a human-occupied room. He regularly advises medium and large companies in their What is Aerium business activities; he notably handled numerous merger and acquisition operations for large clients, and regularly provides advise in the field of clinical trial and research collaboration agreements. In addition, he serves on the board of several companies and foundations, including the Swiss Vaccine Research Institute. He served as Managing General Partner at Sofinnova Investments since 1997 prior to joining Omega in 2021.
Our team
Kai Lin, Ph.D. is joining https://cryptolisting.org/ as the Head of Research and member of the executive team. Dr. Lin has more than 20 years of antiviral drug discovery and development experience in the pharmaceutical industry that contributed to 15 INDs and two NDAs. He is known as a strong scientific leader and virology expert with extensive knowledge on many viral pathogens, including SARS-CoV-2, RSV, HBV and flaviviruses leading drug development of both small molecule and biologics .
Venture capital firm Omega Funds has created and provided initial funding to Aerium Therapeutics, a biotech startup seeking to develop a broadly effective drug for Covid-19. Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers. The antibodies P2G3/P5C3 were tested in the laboratory and in animal studies against forms of the virus that have been shown to escape vaccine immunity including Delta and Omicron variants BA.1, BA.1.1 and BA.2. Dr. Ossipow is Partner at Omega Funds, where he focuses on European investments in the areas of oncology, autoimmune and inflammatory diseases and medtech. Previously, Dr. Ossipow worked with Sectoral Asset Management, a healthcare institutional investor, as a Partner for private investments.